RAPT Therapeutics(RAPT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 RAPT Therapeutics Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif. – August 7, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ended June 30, 2025. Research and development expenses ...